PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Pediatr Infect Dis J. Author manuscript; available in PMC 2009 October 2.
Published in final edited form as:
PMCID: PMC2755569
NIHMSID: NIHMS143574

STEADY-STATE PHARMACOKINETICS OF LOPINAVIR/RITONAVIR IN COMBINATION WITH EFAVIRENZ IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PEDIATRIC PATIENTS

Jennifer R. King, PharmD,* Edward P. Acosta, PharmD,* Ram Yogev, MD, Andrew Wiznia, MD, Joyce Kraimer, MS,§ Bobbie Graham, MS, Vincent Carey, PhD,|| Paula Britto, MS,|| Patrick Jean-Philippe, MD,** John Moye, MD,†† and Douglas Watson, MD‡‡

Abstract

The pharmacokinetics of lopinavir/ritonavir (LPV/RTV) 300 mg/m2 twice daily and efavirenz (EFV) 350 mg/m2 once daily were evaluated in HIV-infected children. The minimum concentrations for LPV contained values above the target range, and the estimated minimum concentrations for EFV contained values below the range. Our data support the current LPV/RTV dose, but EFV 350 mg/m2 may not be sufficient.

Keywords: HIV, pharmacokinetics, lopinavir/ritonavir, efavirenz

An antiretroviral regimen containing efavirenz (EFV) plus lopinavir (LPV) boosted with ritonavir (RTV) in addition to nucleoside reverse transcriptase inhibitors (NRTI) is commonly administered throughout the world as second-line therapy for treatment of the human immunodeficiency virus because it has demonstrated efficacy in NRTI- and protease inhibitor-experienced adults.1 Although the EFV dose remains unchanged, LPV and RTV doses require adjustments when used in combination with EFV, because EFV induces their metabolism.2 Body weight adjusted doses are recommended for this combination in pediatric patients. However, controversy remains as to whether this approach is optimal because body surface area (BSA), which takes into account weight and height, is a better predictor of the physiological changes occurring with age.3 Thus, the objective of protocol P1058 conducted through the International Maternal Pediatric Adolescent AIDS Clinical Trials group was to examine the pharmacokinetics of interacting antiretroviral combinations, specifically EFV, LPV, and RTV, when dosed on a mg/m2 basis in HIV-infected children and adolescents.

METHODS

Study Design

The International Maternal Pediatric Adolescent AIDS Clinical Trial P1058 was an observational pharmacokinetic study of LPV/RTV 300 mg/m2 twice daily (b.i.d.) and EFV 350 mg/m2 once daily (q.d.) in combination with any nucleoside or nucleotide reverse transcriptase inhibitor or fusion inhibitor. Eligible subjects included HIV-infected children, 2–18 years of age receiving at least 2 weeks of antiretroviral therapy. No other non-nucleoside reverse transcriptase inhibitor or protease inhibitor was allowed. Antiretroviral drugs were administered in an open-label fashion. Subjects were excluded if they had hepatic disease likely to affect the metabolism of the studied drugs, bilirubin ≥5.0 × the upper limit of normal, hemoglobin <7.0 g/dL or receiving a drug that might interact with the antiretroviral drugs of interest. A negative pregnancy test was also required at the time of enrollment for females of childbearing capacity. The study was approved by the institutional review board at each site and informed consent or assent when appropriate was obtained from each subject’s parent or legal guardian.

Pharmacokinetic Sampling and Analyses

All subjects underwent a formal pharmacokinetic evaluation in a General Clinical Research Center or clinic setting. Blood samples were collected at 0, 1, 2, 3, 4, 6, 8, and 12 hours post dose. Samples could be collected in the morning or evening; however, the EFV evening dose had to be changed to the morning for at least 1 week before the pharmacokinetic study visit if samples were collected in the morning. LPV, RTV, and EFV plasma concentrations were determined by a modification of a fully validated method using high performance liquid chromatography with ultraviolet detection.4 The assay is linear over a concentration range of 25 to 20,000 ng/mL.

Pharmacokinetic parameters of LPV, RTV, and EFV were determined using noncompartmental methods (WinNonlin version 4.01, Pharsight Corp., Mountain View, CA). The area under the plasma concentration time curve [estimated (Est) AUC24 for EFV and AUC12 for LPV and RTV] was calculated using the linear-up/log-down trapezoidal rule. Maximum plasma concentration (Cmax) and time to maximum concentration (Tmax) were taken directly from the observed concentration-time data. Oral clearance (CL/F) was calculated as dose/AUCτ. Terminal apparent distribution volume (Vz/F) was calculated as dose divided by the product of the elimination rate constant (λz) and AUCτ. The elimination rate constant was determined by linear regression of the terminal elimination phase concentration-time points; elimination half-life (t1/2) was calculated as ln(2)/λz. Regression analysis of the terminal phase was used to estimate the 24-hour concentration of EFV (EstC24 hours).

Statistical Analyses

For each subject, statistical comparisons examined whether the 90% confidence intervals (CIs)of the LPV and EFV geometric mean (GM) AUC and Cmin overlapped with the interval covering 0.5- to 2.0-fold of the target value defined on the basis of studies establishing safety and efficacy of LPV and EFV administered separately.5,6 The target GM (range) for LPV AUC12 was 80 (40 –160) mg × h/L, LPV Cmin was 3.5 (1.75–7) mg/L, EFV AUC24 was 64 (32–124) mg × h/L and EFV C24 hours was 1.8 (0.9 –3.6) mg/L. The 90% CI for LPV and EFV pharmacokinetic parameters when coadministered were compared with the predefined target values for each antiretroviral drug and a substantial overlap between the 2 was indicative of acceptable pharmacokinetics for the combination.

RESULTS

Twenty HIV-infected children between 10 and 16 years of age were enrolled into the study. Intensive pharmacokinetic data were available from 15 patients. Pharmacokinetic parameters could not be determined for 5 patients who received the EFV dose on the evening before the pharmacokinetic visit. Median (range) age, weight, and BSA for the 15 patients were 13 (10 –16) years, 44.5 (26.9 – 63.9) kg, and 1.4 (1.0 –1.7) m2, respectively. The median (range) LPV dose was 289 (132– 407.4) mg/m2 or 9.0 (3.4 –14.9) mg/kg and median (range) EFV dose was 354.2 (132.1– 401.9) mg/m2 or 10.7 (3.4 –13.7) mg/kg.

Pharmacokinetic results for LPV, EFV, and RTV are listed in Table 1. The LPV GM (90% CI) AUC and Cmin were 91.3 (68.5–121.6) mg × h/L and 5.8 (4.2– 8.0) mg/mL, respectively. The LPV Cmin was within the predefined target range for 60% (n = 9) of patients, below the target range for 7% (n = 1) and above the target range for 33% (n = 5). LPV AUC12 was within the predefined target range for 86% (n = 13) of patients, below the target range for 7% (n = 1), and above the target range for 7% (n = 1). The EFV GM (90% CI) AUC24 and EstC24 hours were 44.1 (36.3–53.5) mg × h/L and 0.8 (0.5–1.1) mg/L, respectively. EFV EstC24 was within the predefined target range for 47% (n = 7) of subjects and below the predefined target range for 53% (n = 8) of patients. Except for 1 patient, all of those with an EstC24 hours below the target range (n = 7) had a predose concentration that was also below the target range. EFV AUC24 was within the target range for 86% (n = 13) of patients and below the target range for 14% (n = 2).

TABLE 1
Median (Range) Lopinavir, Ritonavir, and Efavirenz Pharmacokinetics

DISCUSSION

P1058 was an intensive pharmacokinetic study of LPV/RTV 300 mg/m2 b.i.d. in combination with EFV 350 mg/m2 q.d. in HIV-infected children receiving a NRTI-based regimen. The GM (90% CI) for both LPV and EFV AUC were within the target range for all the 15 patients enrolled. In contrast, although the LPV Cmin (GM 90% CI) contained values above the target upper limit of 7 mg/L, the EFV EstC24 hours GM (90% CI) contained values below the target lower limit of 0.9 mg/L.

LPV Cmax, Cmin, and AUC12 observed in our patients in the presence of EFV were 20%, 54%, and 10% higher, respectively, than those observed in adults receiving LPV/RTV 533/133 mg b.i.d. and EFV 600 mg q.d.7 Yet, our results were similar to those observed in HIV-infected children receiving LPV/RTV 300 mg/m2 b.i.d. in combination with EFV 14 mg/kg once daily.8 Of interest, 5 patients (33%) in this study had significantly lower LPV exposure, which is different from our findings where only 1 patient (6.6%) had LPV exposure below the target range of 0.9 mg/L. In the current study, patients received an EFV dose of 350 mg/m2, which approximates 11 mg/kg; the recommended dose is 15 mg/kg. The lower EFV dose in our study may have had a smaller inhibitory effect on LPV metabolism resulting in a smaller number of patients with low LPV exposure. Furthermore, 5 patients in our study had LPV Cmin above the target range of 7 mg/L. Each patient received LPV 400 mg, which was below the recommended 300 mg/m2 dose for 3 patients and approximately 35% higher in 2 patients. Again, higher LPV exposure in these patients is likely the result of the decreased inhibitory effect of the lower EFV dose.

The EFV Cmin and AUC in our patients were 60% and 30% lower, respectively, compared with pediatric and adult patients.9 This difference is also likely due to the lower mg/kg equivalent EFV dose used in our study. However, an evaluation of EFV exposure in 15 South African children receiving a median dose of 352 mg/m2, which was equivalent to 14 mg/kg, revealed that 40% of patients had an estimated Cmin <1 mg/L.10 Another study evaluating EFV exposure in children dosed according to body weight-adjusted dose recommendations observed that 64% of patients had plasma concentrations below the targeted range.11 Taken together, these data suggest that the current weight-based dosing recommendations and the BSA-based dosing of 350 mg/m2 will often result in insufficient EFV exposure.

In conclusion, data from our study support the current strategy of increasing the LPV/RTV dose to 300 mg/m2 in the presence of EFV. However, EFV dosed at 350 mg/m2 may not be adequate in HIV-infected children. This conclusion is supported by several other studies evaluating EFV exposure in HIV-infected children, which also found plasma concentrations lower than expected relative to adult exposures, even when the recommended weight-based dosing was used. Because suboptimal EFV plasma concentrations can increase the development of viral resistance, additional studies are needed to further evaluate BSA-based and the current weight-based dosing of EFV.

Acknowledgments

Supported by grant number U01AI068632 from the National Institute of Allergy and Infectious Diseases.

Footnotes

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.

References

1. Danner S, Burn S, Sylte J, et al. Kaletra (lopinavir/ritonavir) and efavirenz: 72 week safety/efficacy evaluation and phenotypic/genotypic breakpoints in multiple PI experienced patients [abstract I 1925]. Presented at: 41st Inter-science Conference on Antimicrobial Agents and Chemotherapy; December 16 –19, 2001; Chicago, IL.
2. Dailly E, Allavena C, Raffi F, et al. Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz. Br J Clin Pharm. 2004;60:32–34. [PubMed]
3. Bartelink IH, Rademaker CMA, Schobben A, et al. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet. 2006;45:1077–1097. [PubMed]
4. Turner ML, Reed-Walker K, King JR, et al. Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;784:331–341. [PubMed]
5. Saez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003;22:216 –224. [PubMed]
6. Starr SE, Fletcher CV, Spector SA, et al. For the Pediatric AIDS Clinical Trials Group 382 Team. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N Engl J Med. 1999;341:1874 –1881. [PubMed]
7. Hsu A, Isaacson J, Burn S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2003;47:350 –359. [PMC free article] [PubMed]
8. Bergshoeff AS, Fraaij PL, Ndagijimana J, et al. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1 infected children. J Acquir Immune Defic Syndr. 2005;39:63– 68. [PubMed]
9. Sustiva (efavirenz) capsules and tablets [US prescribing information] Princeton, NJ: Bristol-Myers Squibb; 2007.
10. Ren Y, Nuttall JJ, Egbers C, et al. High prevalence of subtherapeutic plasma concentrations of efavirenz in children. J Acquir Immune Defic Syndr. 2007;45:133–136. [PubMed]
11. von Hentig N, Koenigs C, Elanjikal S, et al. Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines. Eur J Med Res. 2006;11:377–380. [PubMed]